Skip to main content
SpringerLink
Log in

Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Grisariu S, Avni B, Batchelor T et al (2010) Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group repot. Blood 115(24):5005–5011

    Article  CAS  Google Scholar 

  2. Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38(2):155–165

    Article  CAS  Google Scholar 

  3. Yasuhito T, Shinya R, Koji I et al (2021) A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B cell lymphoma. Cancer Sci 112:2845–2854

    Article  Google Scholar 

  4. Best RL, LaPointe NE, Azarenko O et al (2021) Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload monomethyl auristatin E(MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol Appl Pharmacol 421:115534

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Yokohama Municipal Citizen’s Hospital, 1-1 Mitsuzawanishi-Cho, Kanagawa-Ku, Yokohama, 221-0855, Japan

    Kohei Shinmura, So Okubo, Saori Kadota, Hitomi Nakayama, Aki Sakurai, Shuhei Kurosawa, Chisako Ito, Yoshinobu Aisa & Tomonori Nakazato

Authors
  1. Kohei Shinmura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. So Okubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saori Kadota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hitomi Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aki Sakurai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuhei Kurosawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chisako Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshinobu Aisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomonori Nakazato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomonori Nakazato.

Ethics declarations

Ethical approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patient. The study was approved by the Ethics Committee of Yokohama Municipal Citizen’s Hospital.

Conflict of interest

The authors declare no competing interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shinmura, K., Okubo, S., Kadota, S. et al. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma. Ann Hematol 102, 223–225 (2023). https://doi.org/10.1007/s00277-022-05039-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-05039-8

Search

Navigation